It has been shown in melanoma patients that CD8+PD-1+ but not CD8+PD-1− T cells in the peripheral blood had increased reactivity to TAA such as NY-ESO1 and MAGE in vitro, indicating enrichment of tumors with tumor-specific immune cells that might be exhausted [24]. This evidence concerns the gene CD8A and melanoma.